'Least Burdensome' Provisions Revisited In FDA Regulatory Science Report
This article was originally published in The Gray Sheet
Executive Summary
FDA is seeking to rein in the device industry's interpretation of the "least burdensome" statutory provisions, which govern how much data regulators may ask for during pre-market reviews